T
Thomas A. Penfound
Researcher at University of Tennessee Health Science Center
Publications - 18
Citations - 751
Thomas A. Penfound is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Streptococcus pyogenes & Antibody. The author has an hindex of 12, co-authored 18 publications receiving 659 citations. Previous affiliations of Thomas A. Penfound include United States Department of Veterans Affairs & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
James B. Dale,Thomas A. Penfound,Thomas A. Penfound,Edna Y. Chiang,Edna Y. Chiang,William J. Walton +5 more
TL;DR: A new 30-valent vaccine containing M protein peptides from GAS serotypes prevalent in North America and Europe was immunogenic in rabbits and evoked bactericidal antibodies against all 30 vaccine serotypes of GAS.
Journal ArticleDOI
Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenes.
Harry S. Courtney,Itzhak Ofek,Itzhak Ofek,Thomas A. Penfound,Victor Nizet,Morgan A. Pence,Bernd Kreikemeyer,Andreas Podbielbski,David L. Hasty,James B. Dale +9 more
TL;DR: The formation of complexes with members of the M protein family is a common mechanism for anchoring LTA on the surface in a manner that contributes to hydrophobicity and to biofilm formation in S. pyogenes, but these activities in some serotypes are dependent on a trypsin-sensitive protein(s).
Journal ArticleDOI
Potential coverage of a multivalent M protein-based group A streptococcal vaccine.
James B. Dale,Thomas A. Penfound,Boubou Tamboura,Samba O. Sow,James P. Nataro,Milagritos D. Tapia,Karen L. Kotloff +6 more
TL;DR: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine.
Journal ArticleDOI
Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes
James B. Dale,James B. Dale,Thomas A. Penfound,Edna Y. Chiang,Valerie Long,Stanford T. Shulman,Bernard Beall +6 more
TL;DR: The results show that the variant M proteins generally do not result in significant differences in opsonization promoted by rabbit antisera raised against the 26-valent vaccine, suggesting that a multivalent M protein vaccine may not permit variant subtypes of group A streptococci to escape in a highly immunized population.
Journal ArticleDOI
Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.
Nicholas D. Hysmith,Nicholas D. Hysmith,Edward L. Kaplan,P. Patrick Cleary,Dwight R. Johnson,Thomas A. Penfound,James B. Dale +6 more
TL;DR: Immune responses to a panel of shared and type-specific antigens before and after new acquisitions of group A streptococci in children were determined.